M Faehling
Overview
Explore the profile of M Faehling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peters S, Pujol J, Dafni U, Domine M, Popat S, Reck M, et al.
Ann Oncol
. 2021 Sep;
33(1):67-79.
PMID: 34562610
Background: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25%...
2.
Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, et al.
Lung Cancer
. 2020 Sep;
148:105-112.
PMID: 32871455
Objective: Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters. Materials And Methods:...
3.
Faehling M, Achenbach J, Staib P, Steffen U, Tessen H, Gaillard V, et al.
J Cancer Res Clin Oncol
. 2018 Apr;
144(7):1375-1383.
PMID: 29687154
Purpose: The controlled phase III trial SATURN demonstrated that maintenance therapy with erlotinib after the first-line platinum-based chemotherapy prolonged progression-free survival (PFS) and overall survival (OS) of non-small cell lung...
4.
Faehling M, Eckert R, Kamp T, Kuom S, Griese U, Strater J, et al.
Lung Cancer
. 2013 Mar;
80(3):306-12.
PMID: 23489557
Introduction: Some patients with advanced NSCLC show prolonged disease stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is not clear how to treat patients who...
5.
Faehling M, Frohnmayer S, Leschke M, Trinajstic-Schulz B, Weber J, Liewald F
Sarcoidosis Vasc Diffuse Lung Dis
. 2011 Nov;
28(2):153-5.
PMID: 22117507
We report a successful pregnancy in a patient with longstanding LAM on treatment with sirolimus. During temporary discontinuation fo sirolimus in early pregnancy, lung function declined but recovered after resumption...
6.
Leschke M, Wadlich A, Waldenmaier S, Faehling M
Internist (Berl)
. 2009 Jul;
50(9):1086, 1088-90, 1092-100.
PMID: 19590842
Commonly, pulmonary hypertension is clinically suspected because of unexplained exertional dyspnoea or as a chance finding in clinical examination revealing signs of right heart failure. The systematic diagnostic approach and...
7.
Faehling M, Leschke M
Dtsch Med Wochenschr
. 2006 Aug;
131(33):1827-8.
PMID: 16902911
No abstract available.
8.
Leschke M, Schwenk B, Bollinger C, Faehling M
Clin Res Cardiol
. 2006 Apr;
95 Suppl 1:i98-102.
PMID: 16598558
Patients with ischaemic heart disease commonly have an impaired glucose tolerance. On the 2004 congress of the ESC, the 75-75-rule was announced, indicating that 75% of all diabetics die of...
9.
Hetzel M, Bachem M, Anders D, Trischler G, Faehling M
Lung
. 2005 Oct;
183(4):225-37.
PMID: 16211459
Objectives And Methods: In idiopathic pulmonary fibrosis (IPF), proliferation of fibroblasts and increased matrix deposition result in pulmonary damage and respiratory insufficiency. We cultured human fibroblasts from lung biopsies of...
10.
Brodbeck-Stoll K, Faehling M, Leschke M
Dtsch Med Wochenschr
. 2003 Dec;
128(49):2612.
PMID: 14655080
No abstract available.